Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Secondary Malignant Neoplasm of Intestinal Tract”

291 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 291 results

Early research (Phase 1)WithdrawnNCT02831179
What this trial is testing

Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor

Who this might be right for
Functional Pancreatic Neuroendocrine TumorMalignant SomatostatinomaMerkel Cell Carcinoma+26 more
Vanderbilt-Ingram Cancer Center
Testing effectiveness (Phase 2)Active Not RecruitingNCT04699188
What this trial is testing

Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Who this might be right for
KRAS G12C Mutant Solid TumorsCarcinoma, Non-Small-Cell LungCarcinoma, Colorectal+7 more
Novartis Pharmaceuticals 344
Testing effectiveness (Phase 2)Looking for participantsNCT07410494
What this trial is testing

Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

Who this might be right for
CancerBreast CancerNon-Small Cell Lung Cancer (NSCLC)+10 more
Essen Biotech 85
Not applicableApproved For MarketingNCT04100694
What this trial is testing

Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor

Who this might be right for
NRG1 FusionPancreatic CancerNon Small Cell Lung Cancer+8 more
Merus B.V.
Testing effectiveness (Phase 2)UnknownNCT05278351
What this trial is testing

Tislelizumab Plus Cetuximab and Irinotecan vs Third-line Standard-of-care in Refractory mCRC

Who this might be right for
Colorectal Neoplasms Malignant
Shanghai Zhongshan Hospital 87
Testing effectiveness (Phase 2)Study completedNCT00385203
What this trial is testing

The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST).

Who this might be right for
Gastrointestinal Stromal TumorsSoft Tissue Sarcomas
AstraZeneca 35
Early research (Phase 1)Study completedNCT03507699
What this trial is testing

Combined Immunotherapy and Radiosurgery for Metastatic Colorectal Cancer

Who this might be right for
Colorectal Neoplasms MalignantLiver Metastases
Sheba Medical Center 19
Early research (Phase 1)Looking for participantsNCT05803382
What this trial is testing

Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers

Who this might be right for
Metastatic Colorectal CarcinomaMetastatic Malignant Solid NeoplasmStage IV Colorectal Cancer AJCC v8+2 more
National Cancer Institute (NCI) 30
Testing effectiveness (Phase 2)Looking for participantsNCT04205968
What this trial is testing

Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers

Who this might be right for
Metastatic Small Intestinal AdenocarcinomaStage III Small Intestinal Adenocarcinoma AJCC v8Stage IIIA Small Intestinal Adenocarcinoma AJCC v8+2 more
SWOG Cancer Research Network 94
Not applicableNot Yet RecruitingNCT05129774
What this trial is testing

Chemoradiotherapy Sequenced Radical Surgery for Colorectal Cancer With PALNM

Who this might be right for
Colorectal Neoplasms MalignantLymph Node ExcisionChemoradiotherapy
Qilu Hospital of Shandong University 40
Testing effectiveness (Phase 2)Ended earlyNCT05983367
What this trial is testing

Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer

Who this might be right for
Colorectal CancerMetastatic Colon Cancer
Inspirna, Inc. 76
Early research (Phase 1)UnknownNCT04660929
What this trial is testing

CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors

Who this might be right for
HER2-positiveAdenocarcinomaBile Duct Cancer+28 more
Carisma Therapeutics Inc 48
Early research (Phase 1)Study completedNCT04330664
What this trial is testing

Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)

Who this might be right for
Advanced CancerMetastatic CancerMalignant Neoplastic Disease
Mirati Therapeutics Inc. 86
Testing effectiveness (Phase 2)Active Not RecruitingNCT02834013
What this trial is testing

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Who this might be right for
Acinar Cell CarcinomaAdenoid Cystic CarcinomaAdrenal Cortical Carcinoma+91 more
National Cancer Institute (NCI) 798
Early research (Phase 1)Ended earlyNCT04628780
What this trial is testing

Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors

Who this might be right for
Non-small-cell Lung CancerSquamous Cell Carcinoma of the Head and NeckRenal Cell Carcinoma+3 more
Pfizer 37
Not applicableUnknownNCT04825470
What this trial is testing

Liver Transplantation for Unresectable GIST Liver Metastases

Who this might be right for
Liver DiseasesLiver CancerLiver Metastases+25 more
Hospital Universitario Virgen de la Arrixaca 50
Large-scale testing (Phase 3)UnknownNCT03686254
What this trial is testing

The Effects of RFA in Combination With Second-line Chemotherapy and Bevacizumab on Unresectable CRLM

Who this might be right for
Colorectal Neoplasms Malignant
Nanfang Hospital, Southern Medical University 160
Early research (Phase 1)Study completedNCT00020579
What this trial is testing

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

Who this might be right for
Cancer
National Institutes of Health Clinical Center (CC) 75
Testing effectiveness (Phase 2)Ended earlyNCT04171700
What this trial is testing

Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes

Who this might be right for
Solid Tumor
pharmaand GmbH 83
Not applicableWithdrawnNCT04985357
What this trial is testing

Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs

Who this might be right for
Stage III Breast CancerStage IV Breast CancerStage III Lung Cancer+35 more
Travera Inc
Load More Results